Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Melanoma 36Carcinoma, Renal Cell 16Prostatic Neoplasms 10Neoplasm Metastasis 10Leukemia, Myeloid, Acute 9Carcinoma, Non-Small-Cell Lung 9Uveal Melanoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 7Clear-cell metastatic renal cell carcinoma 7Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Multiple Myeloma 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Follicular 4Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3

Interventions

Carboplatin 158Paclitaxel 152Bevacizumab 85Gemcitabine 48liposomal doxorubicin 47Taxes 47Topotecan 41Cisplatin 34pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 20Docetaxel 20Drug Therapy 19Magnetic Resonance Spectroscopy 17niraparib 16Doxorubicin 16Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 13rucaparib 12Nivolumab 12Cytoreduction Surgical Procedures 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Chemotherapy, Adjuvant 9130-nm albumin-bound paclitaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Neoplasms × CTLA-4 Antigen × Clear all
NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Completed
100 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡